CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...